AbbVie (NYSE: ABBV) EVP uses shares to cover tax withholding

Rhea-AI Filing Summary

AbbVie Inc. executive Nicholas Donoghoe reported a tax-related share disposition under a compensation plan. On February 27, 2026, he used 12,874 shares of common stock, valued at $232.08 per share, to cover tax withholding. After this transaction, he directly held 74,430 shares of AbbVie common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Donoghoe Nicholas

Role EVP, CHIEF BUS/STRAT OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock, $0.01 par value	12,874	$232.08	$2.99M

Holdings After Transaction: Common Stock, $0.01 par value — 74,430 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donoghoe Nicholas

(Last) (First) (Middle)

1 NORTH WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF BUS/STRAT OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	02/27/2026		F		12,874	D	$232.08	74,430	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ T.O. Odutayo, Attorney-in-Fact for Nicholas J. Donoghoe	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AbbVie (ABBV) executive Nicholas Donoghoe report?

Nicholas Donoghoe reported a tax-withholding disposition of AbbVie shares. On February 27, 2026, he used 12,874 shares of common stock, at $232.08 per share, to satisfy tax obligations tied to equity compensation, rather than executing an open-market sale.

How many AbbVie (ABBV) shares did Nicholas Donoghoe dispose of for taxes?

He disposed of 12,874 AbbVie common shares for tax withholding. The transaction was coded “F,” indicating payment of tax liability by delivering securities, which typically occurs automatically in connection with vesting or exercise of equity awards, not a discretionary market trade.

What price per share was used in Nicholas Donoghoe’s AbbVie (ABBV) tax-withholding transaction?

The disposition used a price of $232.08 per AbbVie share. This price is generally based on market value at the time of the tax-withholding event and is applied to determine how many shares cover the executive’s related tax obligations.

How many AbbVie (ABBV) shares does Nicholas Donoghoe hold after this Form 4 transaction?

After the tax-withholding disposition, Nicholas Donoghoe directly held 74,430 AbbVie common shares. This figure reflects his remaining direct ownership following the use of 12,874 shares to satisfy tax liabilities associated with his equity compensation.

Was Nicholas Donoghoe’s AbbVie (ABBV) Form 4 transaction an open-market stock sale?

The filing shows a tax-withholding disposition, not a regular open-market sale. Code “F” means shares were delivered to cover exercise price or tax liabilities, typically as part of an equity award process rather than a discretionary sale on the open market.

What role does Nicholas Donoghoe hold at AbbVie (ABBV) in this Form 4 filing?

Nicholas Donoghoe is listed as AbbVie’s Executive Vice President and Chief Business/Strategy Officer. His role is identified in the Form 4, which reports his equity-related tax-withholding transaction involving AbbVie common stock on February 27, 2026.